102931Novel drying method for advanced materialsClosedFeasibility StudiesInnovate UKAcapsil is a CE-marked novel first-in-class advanced biomaterial, which has demonstrated effects in wound care. Annually in the UK, 2.2 mill wounds require treatment causing direct costs to the NHS of £5.3 bn. Acapsil accelerates wound healing by 60% and reduces bed-days by 31% for hospital in-patients with acute and chronic wounds and ulcers. Estimates indicate that Acapsil can reduce the costs of wound care by 25-30%. Acapsil is patented in all major markets world-wide. The properties of Acapsil are to a high degree determined by the manufacturing process and currently a single step in the process is preventing large-scale manufacturing. Considerable research has been dedicated to solving this problem and a solution has been found which has been tested and demonstrated to work in a small pilot model. The purpose of this project is to build a full-scale prototype model to reach a final design that can form the basis for a manufacturing line for Acapsil. Without this, it will not be possible to produce Acapsil to cover the medical need. This will mean lost opportunity to help patients with debilitating wounds and loss of important export and job opportunites to the UK.